Recce Pharmaceuticals

Recce Pharmaceuticals ROA

The Return on Assets (ROA) of Recce Pharmaceuticals (RCE.AX) as of Oct 27, 2026 is -175.44 %. In the previous year, Return on Assets (ROA) was -172.61 % — a change of 1.64% (lower).

ROA

-175.44 %

YoY

1.64%

Last updated:

In 2026, Recce Pharmaceuticals's return on assets (ROA) was -175.44 %, a 1.64% increase from the -172.61 % ROA in the previous year.

The Recce Pharmaceuticals ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-302.46 AUD
Jan 1, 2020
-133.06 AUD
Jan 1, 2021
-62.33 AUD
Jan 1, 2022
-87.03 AUD
Jan 1, 2023
-511.66 AUD
Jan 1, 2024
-277.28 AUD
Jan 1, 2025
-172.61 AUD
Jan 1, 2026
-175.44 AUD
The Recce Pharmaceuticals ROA history
YEARROAYoY
-175.44 %+1.64%
-172.61 %-37.75%
-277.28 %-45.81%
-511.66 %+487.91%
-87.03 %+39.64%
-62.33 %-53.16%
-133.06 %-56.01%
-302.46 %+106.61%
-146.39 %-29.14%
-206.58 %+58.79%
-130.09 %+1,341.08%
-9.03 %-95.09%
-183.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

ROA Details

Understanding Recce Pharmaceuticals's Return on Assets (ROA)

Recce Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Recce Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Recce Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Recce Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Recce Pharmaceuticals stock

Return on Assets (ROA) of Recce Pharmaceuticals is -175.44 % in 2026.

Return on Assets (ROA) of Recce Pharmaceuticals changed from -172.61 % to -175.44 %, representing a 1.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Recce Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Recce Pharmaceuticals